Photo Credits: ANI
Coronavirus Vaccine: There is a good news coming out in the Corona Crisis. Yes, the country’s first human trial of Coronavirus Vaccine, Covaxin (Human Trial) will begin this week. In fact, the Indian Council for Medical Research (ICMR), in a joint partnership with Bharat Biotech, has India’s own COVID-19 Vaccine named Covaxin. have developed. This vaccine will be tested on 375 people in the first phase trial and 750 people in the second phase trial. In total, more than 1000 people will be subjected to human trials of this covaxin. The Drug Controller General of India (DCGI) has been approved for the first and second stage trials of the indigenous Kovid-19 vaccine.
The All India Institute of Medical Sciences Patna (AIIMS Patna), one of the 12 medical institutes selected by the ICMR, will begin a clinical human trial of the vaccine this week. Earlier this week, Superintendent of AIIMS Patna, Dr. CM Singh said that the clinical trials would start in the next two days and they are in the process of completing some guidelines and formalities related to other procedures.
It is also a matter of happiness here that testing of this vaccine on animals has been successful and now human trials of this vaccine are about to begin. However, the estimated time frame for the clinical trial is expected to be 6 to 8 months. At the same time, to ensure rapid results of this vaccine, the medical institutes selected by ICMR have been instructed to fast track clinical trials and make it their highest priority project. Let us know that earlier the Nizam Institute of Medical Sciences (NIMS) based in Hyderabad had said that they have started the process of enrollment of participants for the first phase of human trials. ALSO READ: Corona Epidemic: Learn from Dr. Raman R. Gangakhedkar, Senior Scientist of ICMR, the special things related to trial of Covaxin
The codename for this vaccine is BBV152. Covaxin is an inactivated vaccine, made with dead particles of SARS-CoV-2, which disables them from infecting or replicating. Once this vaccine is injected into healthy individuals, antibodies are produced in the body to fight the virus.
The test will be done on healthy people between the age of 22 and 50 years. Even global clinical trials are selecting people of about the same age for their vaccine trials, which can be a matter of concern. For now, it remains to be seen whether this vaccine works on younger people or whether it will work on older people also.